Visiopharm Welcomes Louise Armstrong as Chief Commercial Officer 

May 2nd, 2019

Visiopharm is delighted to announce Louise Armstrong Ph.D. as its new Chief Commercial Officer. A Fellow of the Royal Society of Chemistry, Louise is highly experienced as a Life Science Commercial Director and has an impressive track record in business development in international markets.

Based in London, Louise brings extensive global sales skills with her and will be instrumental in driving Visiopharm’s rapid expansion following significant investment.

“Louise is a veteran of digital pathology, both within research, and on the commercial side, and brings a wealth of accomplishments with her to the Chief Commercial Officer role,” said Michael Grunkin Ph.D., CEO, and co-founder of Visiopharm. “She takes a consultative approach to sales – helping customers find the best possible solution for them – a value that makes her exceptionally well-aligned with the culture at Visiopharm.” 

Louise joins Visiopharm from Random 42, where she developed a commercial strategy for the private equity-backed medical animations agency and has previously driven global growth at Andor Technology as Global Sales Director. In her new role, she will be responsible for the company’s sales team worldwide.

“It’s an exciting time to join Visiopharm,” she said. “With two decades of experience identifying and driving growth opportunities, this is an unmissable opportunity for me to support the company as it continues to grow its presence – and get its message and category-leading products out around the world. I’m looking forward to getting started.”

Following a €13.3 million investment in 2018 to fuel its international growth, Visiopharm is growing rapidly in both revenue and size. With a headcount approaching 100 employees, Visiopharm is the largest quantitative digital pathology software company in the world.

Do you want to know more - contact us

About Visiopharm A/S
Visiopharm® is a world leader in Augmented Pathology™ solutions. Leading biopharmaceutical companies, contract research organizations (CRO), academic medical centers, and diagnostic pathology labs all over the world use Visiopharm’s technology for tissue-based research and diagnostics.

Its solutions use the newest advancements in artificial intelligence and deep learning to make the most comprehensive, highly configurable and accurate services for tissue analysis available on the market today.

Visiopharm was founded in 2001 and is privately owned. The company operates internationally with over 900 licenses in more than 38 countries. Company headquarters are in Denmark’s Medicon Valley, with further offices in London and Broomfield, Colorado.

For Visiopharm logos and pictures: Press Photos